Search the Newsreel

United Therapeutics (UTHR) Earnings Date and Reports 2026 $UTHR

United Therapeutics Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:UTHR) 2026-08-05

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points United Therapeutics Corp (NASDAQ:UTHR) reported exceptional clinical results from its advanced outcomes study, demonstrating ralinepag's …

United Therapeutics earnings on deck after first-quarter miss By Investing.com

United Therapeutics is scheduled to report its second-quarter earnings, with analysts anticipating an improvement from a disappointing first quarter. Investors will be closely watching the performance of its pulmonary arterial hypertension (PAH) franchise and updates on the company's diversification strategy. Despite recent stumbles, Wall …

Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow

Precision Trading with United Therapeutics Corporation (UTHR) Risk Zones

This article provides a precision trading analysis for United Therapeutics Corporation (UTHR), indicating divergent sentiment across various time horizons and suggesting choppy conditions. It highlights a breakdown in progress with elevated downside risk and offers three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along …

United Therapeutics (UTHR) CEO trusts exercise options, sell 9,500 shares

United Therapeutics CEO Martine A. Rothblatt, through family trusts, exercised options for 9,500 shares at a strike price of $135.42 and subsequently sold all 9,500 shares in the low $520s. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, resulted in an approximate …

United Therapeutics CEO Martine Rothblatt sells $4.96 million in stock

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares worth $4.96 million on July 29, 2026, after exercising stock options. The sale was executed under a pre-arranged 10b5-1 trading plan and occurred after an 86% return in the stock over the past …

United Therapeutics (UTHR) CEO exercises 9,500 options, sells shares under plan

United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share and subsequently sold these 9,500 shares on July 29, 2026, under a pre-arranged 10b5-1 trading plan. The shares were sold in multiple open-market transactions …

Is United Therapeutics (UTHR) Undervalued After Its Phase 3 Ralinepag Results?

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

United Therapeutics announced that the ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension (PAH) has been published in The Lancet. The study, which included predominantly pre-treated patients, met its primary endpoint by reducing the risk of a clinical worsening event by 55% compared …

United Therapeutics CEO Rothblatt sells $5 million in shares

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares for approximately $5 million on July 28, 2026, after exercising stock options. This transaction was part of a pre-arranged 10b5-1 trading plan adopted in November 2025. Despite the insider sale, the company has …

Form 4 United Therapeutics Corporation For: 28 July By Investing.com

The article reports on a Form 4 filing for United Therapeutics Corporation (UTHR) which was made on July 28. It provides minimal details about the filing itself, primarily serving as an announcement of the document's existence rather than offering insights into its content. The …

Price to book ratio of United Therapeutics Corporation – HAM:UTH

This page from TradingView displays financial information, specifically the price-to-book ratio, for United Therapeutics Corporation (UTH) on the Hamburg Stock Exchange. The market appears to be closed with no trades showing. The article provides a chart or table for the period, value, and change …

People on the Move: Victor Dzau, M.D., Joins United Therapeutics as Board Member

United Therapeutics Corporation has appointed Victor Dzau, M.D., to its Board of Directors, effective July 22, 2026, as part of its ongoing board refreshment efforts. Dr. Dzau brings extensive experience as a physician-scientist and global health leader, having previously served as President of the …

United Therapeutics (UTHR) awards director 760 restricted stock units

United Therapeutics Corporation (UTHR) director Kevin Tracey was awarded 760 restricted stock units (RSUs) on July 22, 2026, as part of an annual non-employee director equity award. These RSUs convert to one share of common stock each upon vesting, which is anticipated to occur …

Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?

Liquidia Corporation LQDA is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics UTHR boasts six FDA-approved therapies that treat PAH, PH-ILD, and neuroblastoma, a rare pediatric …

United Therapeutics Appoints Victor Dzau To Board Of Directors

(RTTNews) - United Therapeutics Corporation (UTHR), announced on Thursday the appointment of Victor Dzau to its Board, effective immediately. Dzau recently completed a 12-year term as President at the National Academy of Medicine and currently serves as Professor of Medicine and Director of the …

Did a High-Profile Board Addition and ESOP Moves Just Shift United Therapeutics' (UTHR) Investment Narrative?

United Therapeutics (UTHR) awards 760 RSUs to board director Judy D. Olian

United Therapeutics (UTHR) director Judy D. Olian was awarded 760 restricted stock units (RSUs) as an annual non-employee director equity award on July 22, 2026. These RSUs will fully vest on the earlier of one year from the grant date or the next Annual …

United Therapeutics (UTHR) awards RSUs and stock options to director Nilda Mesa

United Therapeutics (UTHR) director Nilda Mesa received annual non-employee director equity awards on July 22, 2026. These awards include 380 restricted stock units and 1,190 stock options, which are expected to vest on the earlier of one year from the grant date or the …

United Therapeutics (UTHR) grants director 2,380 stock options at $527.07

United Therapeutics Corp director Louis W. Sullivan was granted 2,380 stock options at an exercise price of $527.07 per share as part of an annual non-employee director award. These options vest on the earlier of one year from the grant date or the next …

United Therapeutics (UTHR) awards 2,380 stock options to board director

United Therapeutics (UTHR) awarded 2,380 stock options to board director Christopher Patusky on July 22, 2026. These options have an exercise price of $527.07 per share and expire on July 22, 2033. The award is part of the annual non-employee director compensation and vests …

United Therapeutics (UTHR) director Victor Dzau submits initial Form 3

United Therapeutics Corp director Victor J. Dzau has filed an initial Form 3, establishing him as a reporting person for UTHR equity. The filing indicates he is a director, not an officer or ten percent owner, and reports no insider transactions or derivative positions …

United Therapeutics (UTHR) grants director Victor Dzau RSUs and stock options

United Therapeutics (UTHR) director Victor J. Dzau received equity awards, including 730 restricted stock units (RSUs) and 2,300 stock options, on July 22, 2026, as part of his appointment to the Board. These grants were issued under the Non-Employee Director Compensation Program. The stock …

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

United Therapeutics Corporation has announced the appointment of Victor Dzau, M.D., to its Board of Directors, effective July 22, 2026. Dr. Dzau previously served as President of the National Academy of Medicine for 12 years and was Chancellor for Health Affairs at Duke University. …

United Therapeutics (NASDAQ: UTHR) appoints Victor Dzau to board

United Therapeutics Corporation has appointed Victor Dzau, M.D., to its Board of Directors, increasing the board size to 13 members. Dr. Dzau, a renowned physician-scientist and former President of the National Academy of Medicine, will receive equity awards under the 2026 Stock Incentive Plan. …

United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares

United Therapeutics CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 and subsequently sold 9,500 common shares in open-market trades at prices ranging from $523.81 to $537.13. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted …

Liquidia jumps as judge criticizes United Therapeutics in patent dispute

[Judge Gavel Beside Open Law Book With Turning Pages] jittawit.21/iStock via Getty Images Liquidia Corp. (LQDA [https://seekingalpha.com/symbol/LQDA]) rose 8% after a judge in a long-standing patent dispute with United Therapeutics (UTHR [https://seekingalpha.com/symbol/UTHR]) criticized the company's lawyers in a legal filing. United Therapeutics ticked lower …

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

The market expects United Therapeutics (UTHR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

Press Release: United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

United Therapeutics Corporation (NASDAQ: UTHR) announced it will report its Second Quarter 2026 financial results before the market opens on Wednesday, August 5, 2026. The company will also host a webcast and conference call at 9:00 a.m. ET to discuss these results and provide …

United Therapeutics CEO Rothblatt sells $5.05m in stock

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold over $5 million worth of company stock on July 20, 2026, after exercising stock options. These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted in November 2025. Although the stock has seen an …

United Therapeutics (UTHR) CEO executes 9,500-share option exercise and sale

Martine Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), through family trusts, exercised 9,500 stock options and subsequently sold an equal number of shares on July 20, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. After …

United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan

United Therapeutics CEO Martine A. Rothblatt, through family trusts, exercised options for 9,500 shares at $135.42 and subsequently sold all 9,500 common shares across 11 transactions on July 17, 2026, with weighted-average prices ranging from $528.39 to $542.49. These transactions were executed under a …

Lobbying Update: $80,000 of UNITED THERAPEUTICS CORPORATION lobbying was just disclosed

A recent Lobbying Disclosure Act filing revealed that UNITED THERAPEUTICS CORPORATION disclosed $80,000 in lobbying expenditures for Q2 2026, primarily concerning "Issues related to organs and xenotransplantation." The article also details significant insider selling activity, with various executives selling millions of dollars worth of …

United Therapeutics Corp (UTHR)

This article provides a brief overview of United Therapeutics Corp (UTHR) stock performance and key financial metrics. It includes current stock price, daily and 52-week ranges, open and close prices, average volume, market capitalization, shares outstanding, EPS, and P/E ratio.

United Therapeutics (UTHR) Stock Still Looks Like A Bargain After A 185% Run

United Therapeutics (UTHR) has seen its stock rise by 185% over five years, yet analysis suggests it remains undervalued, trading below its fair P/E and peer group average. Recent FDA approval for LungFX and positive phase 3 data for nebulized Tyvaso contribute to a …